

Dimdazenil: Adis Evaluation

Key Points

- An oral partial positive allosteric modulator of the GABA_A receptors, developed by Zhejiang Jingxin Pharmaceutical for the treatment of insomnia.
- Received its first approval on 29 November 2023 in China.
- Approved for short-treatment of insomnia.

Summary

Dimdazenil (Junoenil®) is a small-molecule, oral, partial positive allosteric modulator of the gamma-aminobutyric acid (GABA)_A receptor that is being developed by Zhejiang Jingxin Pharmaceutical in collaboration with Evotec for the treatment of insomnia.

Dimdazenil is designed to overcome issues associated with full GABA_A receptor agonists, such as tolerance, withdrawal symptoms and associated adverse effects.

On 29 November 2023, dimdazenil oral capsules received approval in China for the short-term treatment of insomnia.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2024.